China’s Retail Pharmacy O2O Sales Surge to USD 2.9B in 2021
According to the “China Retail Pharmacy O2O Development Report” released by Minenet, the “online drug...
Drug
China’s Cecolin HPV Vaccine Shows 100% Efficacy in 66-Month Study
Chinese researchers have published 66-month follow-up data from a Phase III clinical study for the...
Dizal Pharma’s Sunvozertinib Gains NMPA Approval for EGFR Mutation NSCLC Trial
China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) announced that it has received clinical trial approval...
Keymed and Lepu’s CMG901 Receives Breakthrough Therapy Designation for Gastric Cancer
The Center for Drug Evaluation (CDE) website indicates that CMG901, a Claudin 18.2 (CLDN18.2)-targeted antibody...
Sirnaomics Initiates Phase I Study of STP705 for Abdominal Fat Reduction
Sino-US siRNA therapy developer Sirnaomics Ltd (HKG: 2257) has announced the first subject dosing in...
Laekna Therapeutics Doses First Patient in LAE001/LAE002 Study for Prostate Cancer
China-based Laekna Therapeutics Shanghai Co., Ltd announced that the first patient has been dosed in...
Innovent’s Tyvyt Combo Shows PFS Benefit in EGFR-Mutant NSCLC
China-based Innovent Biologics Inc. (HKG: 1801) announced positive results from the Phase III ORIENT-31 study...
Hainan Yuekang’s YK-029A Biosimilar Set for BTD in EGFR ex20ins NSCLC
The Center for Drug Evaluation (CDE) website indicates that China-based Hainan Yuekang Biological Medicine Co.,...
Walvax Biotech Enrolls First Subject in Phase III HPV Vaccine Study
China’s Walvax Biotechnology Co., Ltd (SHE: 300142) announced the first subject enrollment for a Phase...
Sinocelltech’s Ripertamab Officially Launched in China for DLBCL Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) announced the first deliveries and prescriptions of its ripertamab...
Innovent’s Tyvyt Shows PFS Benefit in EGFR-Mutant NSCLC at ESMO
China-based Innovent Biologics, Inc. (HKG: 1801) presented results of the ORIENT-31 study for its PD-1...
Luye Pharma’s CD25 Monoclonal Antibody BA1106 Gains NMPA Approval for Clinical Trials
China-based Luye Pharma Group (HKG: 2186) announced that its subsidiary Shandong BoAn Biotechnology Co., Ltd’s...
Fudan-Zhangjiang’s JAK1 Inhibitor FZJ-003 Gel Enters Phase I Trial for Atopic Dermatitis
China-based Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349, SHA: 688505) announced that a Phase I...
HutchMed’s Elunate Shows Survival Benefit in Global CRC Study at ESMO
China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced the results of the pivotal...
Jacobio’s KRAS G12C Inhibitor JAB-21822 Advances to Pivotal Phase II in NSCLC
China’s Jacobio Pharmaceuticals Group Co., Ltd (HKG: 1167) has received approval from the National Medical...
Clover Biopharmaceuticals’ COVID-19 Vaccine SCB-2019 Shows Superior Booster Efficacy in Phase III Trial
China-based Clover Biopharmaceuticals Ltd (HKG: 2197) reported positive Phase III trial results for its COVID-19...
Astellas’ Fezolinetant Hits Menopause Trial Goals in China, Eyes Global Launch
Japan’s Astellas Pharma Inc. (TYO: 4503) announced positive results from a Phase III trial of...
SciClone Pharmaceuticals Doses First Patient in RRx-001 Phase III Study for SCLC
China-based SciClone Pharmaceuticals Inc. (Nasdaq: SCLN) announced that the first patient has been dosed in...
Zelgen Biopharm’s Donafenib Shows Promise in Phase III Study for RAIR-DTC
China-based Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) announced positive results from the Phase III...